rheumatology

Goal disorientation and lack of vision
Biotech

Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data

Phase 2 data on Spyre’s anti-TL1A antibody fell short of expectations, prompting the biotech to deprioritize monotherapy work in the indication.
Nick Paul Taylor Aug 26, 2026 5:40am
Rebranding new name billboard

Canadian CRO Innovaderm rebrands to Indero

Mar 11, 2025 5:45am
Graphic image of a man climbing up a latter in front of a beige background with clouds and a blue splotch of sky

Canadian CRO seeks to grow in rheumatology field with new CEO

Feb 4, 2025 3:05pm